Neisseria meningitidis: Biology, microbiology, and epidemiology

Methods in Molecular Biology

Volumn 799, Issue , 2012, Pages 1-20

  Rouphael, Nadine G ^a   Stephens, David S ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Bacterial infections; Epidemiology; Microbiology; Neisseria meningitidis; Pathogenesis

Indexed keywords

AGE; ANIMAL; BACTERIAL MEMBRANE; BIOLOGICAL MODEL; CLASSIFICATION; EPIDEMIC MENINGITIS; GENETICS; GEOGRAPHY; HUMAN; METABOLISM; MICROBIOLOGY; NEISSERIA MENINGITIDIS; PATHOGENICITY; PHENOTYPE; PHYSIOLOGY; REVIEW; VIRULENCE;

AGE FACTORS; ANIMALS; BACTERIAL CAPSULES; GEOGRAPHY; HUMANS; MENINGITIS, MENINGOCOCCAL; MODELS, BIOLOGICAL; NEISSERIA MENINGITIDIS; PHENOTYPE; VIRULENCE;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; NEISSERIA MENINGITIDIS;

EID: 80555156134     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-346-2_1     Document Type: Chapter

References (136)

1. Weichselbaum A (1887) Ueber die Aetiologie der akuten meningitis cerebrospinalis. Fortschr Med 5:573.
2. Vieusseux M (1805) Mémoire sur la maladie qui a régné à Genéve au printemps de 1805. J Med Clin Pharm 11:163–82.
3. Danielson L, Mann E (1806) A history of a singular and very noted disease, which lately made its appearance in Medfield. Med Agricultural Reg 1:65–9.
4. Greenwood B (1999) Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93:341–53.
5. Kiefer F (1896) Zur differential Diagnose des Erregers der epidemischen Cerebrospinal meningitis und der Gonorrhoea Berl Klin Wochenschr 33:628.
6. Glover J (1918) The cerebrospinal fever epidemic of 1917 at “X” depot. J R Army Med Corps 30:23.
7. Flexner S (1913) The results if the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 17:553.
8. Schwentker F, Gelman S, Long P (1937) The treatment of meningococcic meningitis with sulfonamide. Preliminary report. JAMA 108:1407.
9. Schoenback E, Phair J (1948) The sensitivity of meningococci to sulfadiazine. Am J Hyg 47:177–86.
10. Artenstein MS, Gold R, Zimmerly JG et al (1970) Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 282:417–20.
11. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococca-emia, and Neisseria meningitidis. Lancet 369:2196–210.
12. Sharip A, Sorvillo F, Redelings MD et al (2006) Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr Infect Dis J 25:191–4.
13. Rosenstein NE, Perkins BA, Stephens DS et al (2001) Meningococcal disease. N Engl J Med 344:1378–88.
14. Stephens DS (2009) Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 27 Suppl 2:B71–7.
15. Tettelin H, Saunders NJ, Heidelberg J et al (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:1809–15.
16. Parkhill J, Achtman M, James KD et al (2000) Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404:502–6.
17. Schoen C, Blom J, Claus H et al (2008) Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc Natl Acad Sci USA 105:3473–8.
18. Hotopp JC, Grifantini R, Kumar N et al (2006) Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology 152:3733–49.
19. Davidsen T, Tonjum T (2006) Meningococcal genome dynamics. Nat Rev Microbiol 4:11–22.
20. Hilse R, Hammerschmidt S, Bautsch W et al (1996) Site-specific insertion of IS1301 and distribution in Neisseria meningitidis strains. J Bacteriol 178:2527–32.
21. Uria MJ, Zhang Q, Li Y et al (2008) A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med 205:1423–34.
22. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129:1307–26.
23. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129:1327–48.
24. Snape MD, Pollard AJ (2005) Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 5:21–30.
25. Blacklow RS, Warren L (1962) Biosynthesis of sialic acids by Neisseria meningitidis. J Biol Chem 237:3520–6.
26. Varki A (1997) Sialic acids as ligands in recognition phenomena. FASEB J 11:248–55.
27. Estabrook MM, Griffiss JM, Jarvis GA (1997) Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun 65:4436–44.
28. Kahler CM, Martin LE, Shih GC et al (1998) The (alpha2--> 8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun 66:5939–47.
29. Hobb RI, Tzeng YL, Choudhury BP et al (2010) Requirement of NMB0065 for connecting assembly and export of sialic acid capsular polysaccharides in Neisseria meningitidis. Microbes Infect 12:476–87.
30. Zimmer SM, Stephens DS (2006) Serogroup B meningococcal vaccines. Curr Opin Investig Drugs 7:733–9.
31. Frosch M, Weisgerber C, Meyer TF (1989) Molecular characterization and expression in Escherichia coli of the gene complex encoding the polysaccharide capsule of Neisseria meningitidis group B. Proc Natl Acad Sci USA 86:1669–73.
32. Swartley JS, Marfin AA, Edupuganti S, et al (1997) Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 94:271–6.
33. Aguilera JF, Perrocheau A, Meffre C et al (2002) Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 8:761–7.
34. Raghunathan PL, Jones JD, Tiendrebeogo SR et al (2006) Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002. J Infect Dis 193:607–16.
35. Harrison LH, Shutt KA, Schmink SE et al (2010) Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 201:1208–24.
36. Alonso JM, Gilmet G, Rouzic EM et al (2007) Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9–11 March 2005. Vaccine 25:4125–9.
37. Balmer P, Borrow R, Miller E (2002) Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 51:717–22.
38. Nikaido H (1999) Microdermatology: cell surface in the interaction of microbes with the external world. J Bacteriol 181:4–8.
39. Rahman MM, Kolli VS, Kahler CM et al (2000) The membrane phospholipids of Neisseria meningitidis and Neisseria gonorrhoeae as characterized by fast atom bombardment mass spectrometry. Microbiology 146 (Pt 8):1901–11.
40. Antignac A, Rousselle JC, Namane A et al (2003) Detailed structural analysis of the peptidoglycan of the human pathogen Neisseria meningitidis. J Biol Chem 278:31521–8.
41. Quintela JC, Caparros M, de Pedro MA (1995) Variability of peptidoglycan structural parameters in gram-negative bacteria. FEMS Microbiol Lett 125:95–100.
42. Clarke AJ, Dupont C (1992) O-acetylated peptidoglycan: its occurrence, pathobiological significance, and biosynthesis. Can J Microbiol 38:85–91.
43. Girardin SE, Boneca IG, Viala J et al (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278:8869–72.
44. Jennings HJ, Johnson KG, Kenne L (1983) The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr Res 121:233–41.
45. Gamian A, Beurret M, Michon F et al (1992) Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem 267:922–5.
46. Kahler CM, Stephens DS (1998) Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endo-toxin). Crit Rev Microbiol 24:281–334.
47. Plant L, Sundqvist J, Zughaier S et al (2006) Lipooligosaccharide structure contributes to multiple steps in the virulence of Neisseria meningitidis. Infect Immun 74:1360–7.
48. Zughaier SM, Lindner B, Howe J et al (2007) Physicochemical characterization and biological activity of lipooligosaccharides and lipid A from Neisseria meningitidis. J Endotoxin Res 13:343–57.
49. Mandrell RE, Griffiss JM, Macher BA (1988) Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J Exp Med 168:107–26.
50. Jennings MP, Srikhanta YN, Moxon ER et al (1999) The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology 145:3013–21.
51. Mandrell RE, Zollinger WD (1977) Lipopolysaccharide serotyping of Neisseria meningitidis by hemagglutination inhibition. Infect Immun 16:471–5.
52. Zughaier SM, Tzeng YL, Zimmer SM et al (2004) Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun 72:371–80.
53. Zughaier S, Steeghs L, van der Ley P et al (2007) TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A. Vaccine 25:4401–9.
54. Braun JM, Blackwell CC, Poxton IR et al (2002) Proinflammatory responses to lipooligosaccharide of Neisseria meningitidis immunotype strains in relation to virulence and disease. J Infect Dis 185:1431–8.
55. Brandtzaeg P, Kierulf P, Gaustad P et al (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195–204.
56. Brandtzaeg P, Bryn K, Kierulf P et al (1992) Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest 89: 816–23.
57. Greenfield S, Sheehe PR, Feldman HA (1971) Meningococcal carriage in a population of “normal” families. J Infect Dis 123:67–73.
58. Stephens DS (1999) Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 353:941–2.
59. Caugant DA, Hoiby EA, Magnus P et al (1994) Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 32:323–30.
60. Pinner RW, Spellman PA, Stephens DS (1991) Evidence for functionally distinct pili expressed by Neisseria meningitidis. Infect Immun 59:3169–75.
61. Virji M, Alexandrescu C, Ferguson DJ et al (1992)Variations in the expression of pili: the effect on adherence of Neisseria meningitidis to human epithelial and endothelial cells. Mol Microbiol 6:1271–9.
62. Merz AJ, So M (2000) Interactions of pathogenic neisseriae with epithelial cell membranes. Annu Rev Cell Dev Biol 16:423–57.
63. Stephens DS, McGee ZA (1981) Attachment of Neisseria meningitidis to human mucosal surfaces: influence of pili and type of receptor cell. J Infect Dis 143:525–32.
64. Proft T, Baker EN (2009) Pili in Gram-negative and Gram-positive bacteria-structure, assembly and their role in disease. Cell Mol Life Sci 66:613–35.
65. Kahler CM, Martin LE, Tzeng YL et al (2001) Polymorphisms in pilin glycosylation Locus of Neisseria meningitidis expressing class II pili. Infect Immun 69:3597–604.
66. Marceau M, Forest K, Beretti JL et al (1998) Consequences of the loss of O-linked glycosylation of meningococcal type IV pilin on piliation and pilus-mediated adhesion. Mol Microbiol 27:705–15.
67. Callaghan MJ, Jolley KA, Maiden MC (2006) Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis. Infect Immun 74:5085–94.
68. Virji M, Watt SM, Barker S et al (1996) The N-domain of the human CD66a adhesion molecule is a target for Opa proteins of Neisseria meningitidis and Neisseria gonorrhoeae. Mol Microbiol 22:929–39.
69. Virji M, Makepeace K, Ferguson DJ et al (1992) Expression of the Opc protein correlates with invasion of epithelial and endothelial cells by Neisseria meningitidis. Mol Microbiol 6:2785–95.
70. Virji M, Evans D, Hadfield A et al (1999) Critical determinants of host receptor targeting by Neisseria meningitidis and Neisseria gonorrhoeae: identification of Opa adhesiotopes on the N-domain of CD66 molecules. Mol Microbiol 34:538–51.
71. Hill DJ, Griffiths NJ, Borodina E et al (2010) Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond) 118:547–64.
72. Perkins-Balding D, Ratliff-Griffin M, Stojiljkovic I (2004) Iron transport systems in Neisseria meningitidis. Microbiol Mol Biol Rev 68:154–71.
73. Schryvers AB, Stojiljkovic I (1999) Iron acquisition systems in the pathogenic Neisseria. Mol Microbiol 32:1117–23.
74. Tzeng YL, Stephens DS (2000) Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect 2:687–700.
75. Massari P, Ram S, Macleod H et al (2003) The role of porins in neisserial pathogenesis and immunity. Trends Microbiol 11:87–93.
76. Vermont CL, van Dijken HH, Kuipers AJ et al (2003) Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun 71:1650–5.
77. Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19:2688–91.
78. Frasch CE, Zollinger WD, Poolman JT (1985) Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7:504–10.
79. Slaterus KW (1961) Serological typing of meningococci by means of micro-precipitation. Antonie Van Leeuwenhoek 27:305–15.
80. Branham S (1953) Serological relationships among meningococci. Bact Rev 17:175–88.
81. Vogel U (2010) Molecular epidemiology of meningococci: Application of DNA sequence typing. Int J Med Microbiol 300(7):415–20.
82. Caugant DA, Froholm LO, Bovre K et al (1986) Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci USA 83:4927–31.
83. Bevanger L, Bergh K, Gisnas G et al (1998) Identification of nasopharyngeal carriage of an outbreak strain of Neisseria meningitidis by pulsed-field gel electrophoresis versus phenotypic methods. J Med Microbiol 47:993–8.
84. Weis N, Lind I (1998) Epidemiological markers in Neisseria meningitidis: an estimate of the performance of genotyping vs phenotyping. Scand J Infect Dis 30:69–75.
85. Maiden MC, Bygraves JA, Feil E et al (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 95:3140–5.
86. Mothershed EA, Sacchi CT, Whitney AM et al (2004) Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 42:320–8.
87. Yazdankhah SP, Kriz P, Tzanakaki G et al (2004) Distribution of serogroups and geno-types among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 42:5146–53.
88. Wu HM, Harcourt BH, Hatcher CP et al (2009) Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 360:886–92.
89. Baart GJ, Zomer B, de Haan A et al (2007) Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes. Genome Biol 8:R136.
90. Price ND, Papin JA, Schilling CH et al (2003) Genome-scale microbial in silico models: the constraints-based approach. Trends Biotechnol 21:162–9.
91. Papin JA, Price ND, Wiback SJ et al (2003) Metabolic pathways in the post-genome era. Trends Biochem Sci 28:250–8.
92. Jyssum K, Borchgrevink B, Jyssum S (1961) Glucose catabolism in Neisseria meningitidis. 1. Glucose oxidation and intermediate reactions of the Embden-Meyerhof pathway. Acta Pathol Microbiol Scand 53:71–83.
93. Frantz ID (1942) Growth requirements of the meningococcus. J Bacteriol 1942;43:757–61.
94. Chapin (1918) Carbon dioxide in the primary cultivation of the gonococcus. J Infect Dis 19:558–61.
95. Grossowicz N (1945) Growth requirements and metabolism of Neisseria intracellularis. J Bacteriol 50:109–15.
96. Erwin AL, Gotschlich EC (1996) Cloning of a Neisseria meningitidis gene for L-lactate dehydrogenase (L-LDH): evidence for a second meningococcal L-LDH with different regulation. J Bacteriol 178:4807–13.
97. Leighton MP, Kelly DJ, Williamson MP et al (2001) An NMR and enzyme study of the carbon metabolism of Neisseria meningitidis. Microbiology 147:1473–82.
98. Port JL, DeVoe IW, Archibald FS (1984) Sulphur acquisition by Neisseria meningitidis. Can J Microbiol 30:1453–7.
99. Cohn AC, MacNeil JR, Harrison LH et al (2010) Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 50:184–91.
100. Fischer M, Hedberg K, Cardosi P et al (1997) Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 16:979–83.
101. Jackson LA, Schuchat A, Reeves MW et al (1995) Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 273:383–9.
102. Rosenstein NE, Perkins BA, Stephens DS et al (1999) The changing epidemiology of meningococcal disease in the United States, 1992– 1996. J Infect Dis 180:1894–901.
103. Cartwright K, Noah N, Peltola H (2001) Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6–8 October, 2000. Vaccine 19:4347–56.
104. Trotter CL, Andrews NJ, Kaczmarski EB et al (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–7.
105. Maiden MC, Ibarz-Pavon AB, Urwin R et al (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197:737–43.
106. Trotter CL, Ramsay ME (2007) Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31:101–7.
107. Lepeyssonnie (1963) La méningite cérébro-spinale en Afrique. Bull WHO 28:53–114.
108. Molesworth AM, Cuevas LE, Connor SJ et al (2003) Environmental risk and meningitis epidemics in Africa. Emerg Infect Dis 9:1287–93.
109. Greenwood BM, Bradley AK, Wall RA et al (1985) Meningococcal disease and season in sub-Saharan Africa. Lancet 2:829–30.
110. Lewis R, Nathan N, Diarra L et al (2001) Timely detection of meningococcal meningitis epidemics in Africa. Lancet 358:287–93.
111. Artenstein MS, Rust JH Jr., Hunter DH et al (1967) Acute respiratory disease and meningococcal infection in army recruits. JAMA 201:1004–7.
112. Young LS, LaForce FM, Head JJ et al (1972) A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med 287:5–9.
113. Safadi MA, Cintra OA (2010) Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res32:263–71.
114. Wang JF, Caugant DA, Li X et al (1992) Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People’s Republic of China. Infect Immun 60:5267–82.
115. Hart CA, Cuevas LE (1997) Meningococcal disease in Africa. Ann Trop Med Parasitol 91:777–85.
116. Wyle FA, Artenstein MS, Brandt BL et al (1972) Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126:514–21.
117. Oster P, Lennon D, O’Hallahan J et al (2005) MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191–6.
118. Rodriguez AP, Dickinson F, Baly A et al (1999) The epidemiological impact of anti-meningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz 94:433–40.
119. Galloway Y, Stehr-Green P, McNicholas A et al (2009) Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 38:413–8.
120. Dull PM, Abdelwahab J, Sacchi CT et al (2005) Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj. J Infect Dis 191:33–9.
121. Lingappa JR, Al-Rabeah AM, Hajjeh R et al (2003) Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 9:665–71.
122. Wilder-Smith A, Goh KT, Barkham T et al (2003) Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 36:679–83.
123. Hahne SJ, Gray SJ, Jean F et al (2002) W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 359:582–3.
124. Efron AM, Sorhouet C, Salcedo C et al (2009) W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J Clin Microbiol 47:1979–80.
125. Koumare B, Ouedraogo-Traore R, Sanou I et al (2007) The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 25 Suppl 1:A37–41.
126. Traore Y, Njanpop-Lafourcade BM, Adjogble KL et al (2006) The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 43:817–22.
127. Decosas J, Koama JB (2002) Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2:763–5.
128. Ouedraogo-Traore R, Hoiby EA, Sanou I et al (2002) Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scand J Infect Dis 34:804–7.
129. Materu S, Cox HS, Isaakidis P et al (2007) Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis 13:944–5.
130. Boisier P, Nicolas P, Djibo S et al (2007) Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 44:657–63.
131. Gagneux SP, Hodgson A, Smith TA et al (2002) Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 185:618–26.
132. Harrison LH, Dwyer DM, Maples CT (1999) Risk of meningococcal infection in college students. JAMA 281:1906–10.
133. Kaplan SL, Schutze GE, Leake JA et al (2006) Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 118:e979–84.
134. Shepard CW, Rosenstein NE, Fischer M (2003) Neonatal meningococcal disease in the United States, 1990 to 1999. Pediatr Infect Dis J 22:418–22.
135. Caugant DA (2008) Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect Genet Evol 8:558–65.
136. Caugant DA, Maiden MCJ (2009) Meningococcal carriage and disease – population biology and evolution Vaccine 27:B64–B70.